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ABSTRACT 17 
The AMP-activated protein kinase (AMPK) is a key regulator of cellular and whole body energy 18 
homeostasis, which acts to restore energy homoeostasis whenever cellular energy charge is 19 
depleted. Over the last two decades, it has become apparent that AMPK regulates a number of other 20 
cellular functions and has specific roles in cardiovascular tissues, acting to regulate cardiac 21 
metabolism and contractile function as well as promoting anti-contractile, anti-inflammatory and 22 
anti-atherogenic actions in blood vessels. In this review, we will discuss the role of AMPK in the 23 
cardiovascular system, including the molecular basis of mutations in AMPK that alter cardiac 24 
physiology and the proposed mechanisms by which AMPK regulates vascular function under 25 
physiological and pathophysiological conditions.  26 
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The AMP-activated protein kinase (AMPK) is the central component of a signalling pathway that 27 
regulates the switch between anabolism and catabolism, as well as many other aspects of cell 28 
function1-3. In this review we focus on the physiological roles of AMPK within the cardiovascular 29 
system, although we will start by discussing general features that apply in all mammalian cell types. 30 
Readers are also referred to two other recent reviews of the role of AMPK in cardiovascular disease 31 
4, 5. 32 
STRUCTURE AND REGULATION OF AMPK 33 
Occurrence of subunit isoforms 34 
AMPK exists universally as heterotrimeric complexes containing catalytic α subunits and 35 
regulatory β and γ subunits, which occur as multiple isoforms (α1/α2; β1/β2; γ1/γ2/γ3) encoded by 36 
distinct genes. These could give rise in principle to twelve heterotrimeric combinations, although 37 
specific combinations appear to be favoured in specific cell types. For example, although skeletal 38 
muscle expresses mRNAs encoding all seven subunit isoforms, assays of immunoprecipitated 39 
isoforms suggest that AMPK activity in human skeletal muscle is accounted for by just three 40 
combinations: α1β2γ1, α2β2γ1 and α2β2γ36. 41 
 The domain organization of the seven AMPK subunit isoforms are shown in Fig. 1, and a 42 
representation of a crystal structure for the human α1β2γ1 heterotrimer7 is shown in Fig. 2. Similar 43 
structures of the α2β1γ18 and α1β1γ19 complexes are available. 44 
The α subunits 45 
The α subunits contain a kinase domain (α-KD) at their N-termini, with the small N-lobe (yellow in 46 
Figs.1 and 2) and larger C-lobe (green) typical of all protein kinases. The substrate Mg.ATP2- binds 47 
in a deep cleft between these lobes, occupied in the structure in Fig. 2 by the non-specific kinase 48 
inhibitor staurosporine. Isolated α-KDs are only significantly active after phosphorylation by 49 
upstream kinases at a conserved threonine, usually referred to as Thr172. Thr172 phosphorylation is 50 
a good marker for AMPK activity, and Western blotting using phosphospecific antibodies against 51 
this site is often used as a semi-quantitative measure of AMPK activity. However, this ignores the 52 
effects of allosteric activation of AMPK, a problem that can be overcome by also addressing the 53 
phosphorylation state of a downstream target such as acetyl-CoA carboxylase (ACC). 54 
Salt & Hardie AMPK in the cardiovascular system 3
 The α-KD is followed by a small globular domain termed the autoinhibitory domain (AID, 55 
orange) that, when AMP is not bound to the γ subunit, binds to both the N- and C-lobes of the KD 56 
and thus causes inhibition7. The AID is connected to the C-terminal domain (α-CTD, red) by the α-57 
linker (blue), a region of extended polypeptide that interacts with the γ subunit when AMP is bound 58 
at site 3 (as is the case in Fig. 2), thus pulling the AID away from this inhibitory position. 59 
The β subunits 60 
Two well-conserved regions within the β subunits are the C-terminal domain (β-CTD, silver-grey), 61 
which forms the “core” of the heterotrimeric complex, and the central carbohydrate-binding module 62 
(β-CBM, silver-blue). The β-CBM is related to carbohydrate-binding domains usually occurring in 63 
enzymes that metabolize starch or glycogen, which localize those enzymes on their polysaccharide 64 
substrate. Consistent with this, the β-CBM causes a proportion of AMPK in cells to bind to the 65 
surface of glycogen particles10-12. In all three structures of mammalian heterotrimers, the β-CBM 66 
interacts with the N-lobe of the α subunit KD, with its glycogen-binding site (defined by binding of 67 
the oligosaccharide β-cyclodextrin) at the top in the view of Fig. 2. 68 
 What is the function of glycogen binding by AMPK? The muscle and liver isoforms of glycogen 69 
synthase, which are also bound to glycogen particles, are physiological targets for AMPK13, 14, and 70 
one function may be to co-localize AMPK with them. The β-CBM is also of interest because the 71 
cleft between it and the N-lobe of the α subunit forms the binding site for activators such as 72 
A769662 and 9918. This site has been termed the Allosteric Drug and Metabolite (ADaM) site15, 73 
and is discussed further below. 74 
The γ subunits 75 
All γ subunits contain four tandem repeats of a sequence motif known as a CBS motif. In other 76 
proteins, pairs of CBS motifs often form binding sites for regulatory ligands containing adenosine16; 77 
in the AMPK-γ subunits they bind the regulatory nucleotides AMP, ADP or and ATP17. Two views 78 
of a structure for the γ1 subunit, containing three molecules of bound AMP18, are shown in Fig. 3. 79 
The two pairs of repeats (CBS1:CBS2 and CBS3:CBS4) assemble in a pseudosymmetrical “head-80 
to-head” manner. The γ subunit thus forms a structure like a flattened disc (seen from different 81 
faces in Fig. 3) with one CBS repeat in each quadrant, generating four potential ligand-binding 82 
clefts in the centre. However, one of these appears to be unused, perhaps because conserved 83 
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aspartate residues in CBS1, CBS3 and CBS4 that bind the ribose ring of adenine nucleotides in sites 84 
1, 3 and 4 are absent from CBS218. Interestingly, mutation of any of these three aspartate residues 85 
interferes with multiple effects of AMP on kinase activity19, suggesting that occupancy of all three 86 
sites may be required for full activation. 87 
Identity of upstream kinases 88 
Identifying the upstream kinases that phosphorylate Thr172 was a difficult challenge, eventually 89 
solved by genome-wide biochemical screens that identified three upstream kinases in budding yeast 90 
20, 21.  The mammalian kinases with catalytic domains most closely related to these were LKB1 and 91 
the Ca2+/calmodulin-dependent kinase CaMKK2 (CaMKKβ), and evidence was soon obtained that 92 
both could act as physiological upstream kinases in mammalian cells22-27. The discovery that LKB1 93 
was an upstream kinase for AMPK was particularly interesting, because LKB1 had previously been 94 
identified to be a tumor suppressor28. Phosphorylation of Thr172 by CaMKK225-27 represents a 95 
mechanism by which hormones that increase cytosolic Ca2+ can activate AMPK in the absence of 96 
energy stress. 97 
GENERAL FEATURES OF AMPK REGULATION 98 
Regulation by the canonical energy stress mechanism 99 
It might be expected that a system that monitors cellular energy status would sense ATP and ADP 100 
but, interestingly, all metabolic enzymes known to directly monitor cellular energy charge 101 
(glycogen phosphorylase, 6-phosphofructo-1-kinase, fructose-1,6-bisphosphatase) primarily sense 102 
AMP and ATP, as does AMPK. The principal source of AMP in cells is thought to be the adenylate 103 
kinase reaction (2ADP ↔ ATP + AMP), which appears to operate close to equilibrium in most cells 104 
so that the AMP:ATP ratio will vary as the square of the ADP:ATP ratio29. The former is therefore 105 
a more sensitive indicator of falling energy status than the latter. 106 
 Binding of AMP activates AMPK by three complementary mechanisms, of which the first two 107 
are mimicked by ADP at higher concentration, while all three are antagonized by ATP: (i) 108 
inhibition of Thr172 dephosphorylation by protein phosphatases; (ii) promotion of Thr172 109 
phosphorylation by LKB1; and (iii) allosteric activation30, 31. The structural model shown in Fig. 2 110 
suggests a mechanism, for which there is now supporting evidence7, to explain mechanisms (i) and 111 
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(iii). When AMP is bound at site 3, the α-linker interacts with the surface of the γ subunit 112 
containing that site (Fig. 2)7, 32. AMPK heterotrimers contain two rather distinct regions, the 113 
“catalytic module” (β-CBM, KD, AID, top/front section in Fig. 2) and the “nucleotide-binding 114 
module” (γ subunit, β-CTD, α-CTD, bottom/rear section in Fig. 2). The “hinge” connecting them is 115 
the α-linker, and release of the α-linker on binding of ATP rather than AMP at site 3 is envisaged 116 
to allow the two modules to move apart, causing the AID to rotate back into its inhibitory position 117 
behind the α-KD. This conformational change would also increase accessibility of Thr172 to 118 
protein phosphatases, which in the AMP-bound conformation of Fig. 2 is around the back, located 119 
in a deep cleft between the two modules. This model therefore explains not only how AMP binding 120 
at site 3 causes allosteric activation, but also why it protects against Thr172 dephosphorylation, 121 
with binding of ATP antagonizing both effects. 122 
Multiple mechanisms of pharmacological activation of AMPK 123 
 A selection of compounds commonly used to activate AMPK experimentally are listed in Table 124 
1. Those in Class 1, including the antidiabetic drug metformin and berberine (derived from 125 
traditional Chinese medicine) inhibit Complex I of the mitochondrial respiratory chain, while those 126 
in class 2, including 2-deoxyglucose, inhibit glycolysis. Both classes activate AMPK indirectly by 127 
increasing cellular AMP:ATP ratios33. These compounds are frequently used to activate AMPK 128 
experimentally, and studies utilizing them are described later in this review. However, because they 129 
work by depleting cellular ATP, they should not be regarded as specific AMPK activators and any 130 
results obtained with them should ideally be followed up using genetic approaches, such as the use 131 
of AMPK knockouts. 132 
 The third class of activator includes the widely used compound 5-aminoimidazole-4-133 
carboxamide ribonucleoside (AICAR), a nucleoside that is taken up into cells and converted to the 134 
equivalent nucleotide, ZMP. An important caveat here is that although ZMP is an AMP analog that 135 
mimics the effects of AMP to activate AMPK, it is about 50-fold less potent than AMP itself34. 136 
Because ZMP accumulates to millimolar concentrations inside cells AICAR does cause AMPK 137 
activation, but ZMP also has off-target effects. For example, it is known to mimic the effects of 138 
AMP on phosphorylase35 and fructose-1,6-bisphosphatase36 as well as AMPK. Another problem 139 
with AICAR is that it is an adenosine analogue and, while it does not appear to bind directly to 140 
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adenosine receptors, in incubated cell systems it competes with endogenous adenosine for reuptake 141 
into cells by adenosine transporters, so can have adenosine-like effects 37. 142 
 A more specific activator that works via a related mechanism (class 4) is C13, which is taken up 143 
by cells and converted by cellular esterases to the AMP analog C2, a very potent AMPK activator38 144 
although only for α1- and not α2-containing complexes39. Despite its selectivity for the α1 isoform, 145 
C2 binds to the γ subunit. Although the AMP and C2 binding sites overlap, they are not identical40. 146 
 The other molecules of choice for selective activation of AMPK are those binding at the ADaM 147 
site located between the β-CBM and the N-lobe on the α subunit, such as A769662 and 991 (class 148 
5)8. All compounds binding this site are more potent activators of complexes containing AMPK-β1 149 
rather than β2, and most are essentially β1-selective (Table 1). Using AMPK phosphorylated on 150 
Thr172, these activators cause a modest degree of allosteric activation (up to 4-fold) and, by 151 
inhibiting dephosphorylation, also promote net Thr172 phosphorylation41, 42. More remarkably, they 152 
cause a much larger allosteric activation (up to 65-fold) of AMPK that is not phosphorylated on 153 
Thr172, and this effect is synergistic with AMP43. At present, almost all of the activators known to 154 
bind at this site are synthetic compounds derived from high-throughput screens, although there is 155 
much speculation in the field that there is a naturally occurring ligand, hence the appearance of 156 
“metabolite” in its name15. However, no natural ligands occurring in animal cells that bind the 157 
ADaM site have yet been found. Salicylate, the natural plant product from which acetyl salicylic 158 
acid (ASA, aspirin) was derived, does activate AMPK by binding this site9, 44. 159 
 It should also be noted that there are currently no specific pharmacological inhibitors of AMPK; 160 
compound C (dorsomorphin) is sometimes claimed to be a specific inhibitor, but this is not the 161 
case45. 162 
TARGETS AND PATHWAYS DOWNSTREAM OF AMPK 163 
Catabolic effects switched on by AMPK 164 
Once activated by energy stress, AMPK switches on catabolic pathways generating ATP, while 165 
switching off anabolic pathways and other processes consuming ATP, thus acting to restore energy 166 
homeostasis. This topic has been discussed in more detail in previous reviews1-3. Examples of 167 
catabolic processes acutely switched on include cellular glucose uptake mediated by GLUT1 and 168 
GLUT4. Activation of GLUT1 may occur via phosphorylation of the thioredoxin interacting protein 169 
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TXNIP46, while enhanced GLUT4 translocation to the plasma membrane in muscle appears to 170 
occur, at least in part, by phosphorylation of TBC1D1, which modulates trafficking of GLUT4-171 
containing vesicles47. AMPK activation also enhances GLUT4 expression48, in part via 172 
phosphorylation of the histone deacetylase HDAC5, promoting binding of 14-3-3 proteins and 173 
consequent retention of HDAC5, a transcriptional inhibitor, in the cytoplasm49, 50. AMPK can also 174 
cause a short-term activation of glycolysis via phosphorylation of PFKFB251 and PFKFB352, 175 
isoforms of the bifunctional enzyme that synthesizes and breaks down fructose-2,6-bisphosphate, a 176 
key allosteric activator of 6-phosphofructo-1-kinase and hence glycolysis. PFKFB2 is expressed in 177 
the heart, while PFKFB3 occurs as an “inducible” form whose expression in monocytes and 178 
macrophages is induced by inflammatory mediators such as lipopolysaccharide53. Phosphorylation 179 
of PFKFB2 or PFKFB3 at equivalent sites near their C-termini increases the synthesis of fructose-180 
2,6-bisphosphate and hence promotes glycolysis during hypoxia in heart and in activated 181 
monocytes/macrophages, respectively. This may enhance survival of these cells during periods of 182 
hypoxia or ischemia. 183 
 Although AMPK can therefore activate glucose uptake and glycolysis in specific cell types, in 184 
the longer term it tends to promote instead the more glucose-sparing and energy-efficient oxidative 185 
metabolism. In skeletal muscle54, 55 and liver56, AMPK activates fatty acid oxidation by inhibiting 186 
the ACC1/ACC2 isoforms of acetyl-CoA carboxylase to reduce malonyl-CoA, an inhibitor of the 187 
uptake of fatty acids into mitochondria. AMPK promotes the expression of TCA cycle enzymes57, 188 
as well as mitochondrial biogenesis, which it achieves by increasing the expression/activity of the 189 
transcriptional co-activator PGC-1α, either by direct phosphorylation triggering a positive feedback 190 
effect on its own expression58, or by enhancing its deacetylation by SIRT159. PGC-1α acts as a co-191 
activator for several transcription factors involved in mitochondrial biogenesis and oxidative 192 
metabolism, including myocyte enhancer factor-2 (MEF2), nuclear respiratory factors-1/-2 193 
(NRF1/2), and PPAR-α and –δ60. Despite this evidence that AMPK promotes oxidative 194 
metabolism, in mice with a skeletal/cardiac muscle-specific knockout of both AMPK-β subunits, 195 
although the mice displayed evidence of dilated cardiomyopathy the rate of glucose and fatty acid 196 
oxidation in hearts perfused under normoxic conditions ex vivo was normal61. 197 
 A final catabolic pathway switched on by AMPK is autophagy, brought about via direct 198 
phosphorylation of the protein kinase that triggers that process, ULK162. By triggering digestion of 199 
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cellular contents, autophagy may be critical in enhancing cell survival during periods of acute 200 
nutrient starvation, such as during ischemia in cardiac muscle. However, it has also been suggested 201 
that excessive autophagy might also contribute to cell damage during ischemia/reperfusion63. 202 
Anabolic pathways switched off by AMPK 203 
As well as its classical roles in inhibiting fatty acid and sterol synthesis34, AMPK inactivates key 204 
enzymes and regulatory proteins involved in triglyceride/phospholipid synthesis64, glycogen 205 
synthesis13, 14, rRNA synthesis65, and protein synthesis. The latter is inhibited both at the elongation 206 
step by phosphorylation and activation of elongation factor-2 (EF2) kinase66, and at the initiation 207 
step by inactivation of the mechanistic target-of-rapamycin complex-1 (mTORC1) by multiple 208 
mechanisms67, 68. By inhibiting mTORC1, AMPK would also be expected to oppose hypertrophy in 209 
organs such as the heart, which in most cases is considered to be a deleterious process. 210 
ROLE OF AMPK IN THE HEART 211 
Role in the response to cardiac ischemia 212 
It was reported in 1995 that AMPK was activated by no-flow ischemia in perfused rat hearts, an 213 
effect associated with high rates of fatty acid oxidation during reperfusion69. AMPK is also 214 
activated in the heart by increased workload70. The role of AMPK in cardiac ischemia has 215 
subsequently been addressed using mouse models where AMPK is down-regulated or absent. The 216 
first was a transgenic model where an inactive AMPK-α2 subunit was expressed in both skeletal 217 
and cardiac muscle. By competing with endogenous α subunits for available β and γ subunits, the 218 
over-expressed inactive α2 subunit down-regulates endogenous α1 and α2, and thus acts as a 219 
dominant negative mutant. There was no major phenotype under unstressed conditions, but during 220 
low-flow ischemia there was a failure to enhance glucose uptake and glycolysis, while during 221 
subsequent reperfusion there was less fatty acid oxidation, lower ATP levels and poorer recovery of 222 
contractile function71. The degree of damage to the myocardium was also greater, suggesting that 223 
AMPK exerts a cardioprotective effect overall, even though stimulation of fatty acid oxidation 224 
during reperfusion may be deleterious69. Using the same model, evidence was obtained that AMPK 225 
was required for increased autophagy during ischemia72. 226 
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 Next to be studied were conditional knockouts of the upstream kinase LKB1 in both skeletal and 227 
cardiac muscle. The basal activity of AMPK-α2 complexes in the heart was completely abolished, 228 
and did not increase in response to no-flow ischemia or anoxia, correlating with a complete lack of 229 
ACC phosphorylation at the AMPK site. The AMP:ATP and ADP:ATP ratios were also elevated to 230 
a greater extent during no-flow ischemia than in control hearts, confirming that AMPK was 231 
protecting the cells against energetic stress. Surprisingly, the activity of AMPK-α1 complexes was 232 
almost unaffected by LKB1 knockout, and still increased in response to ischemia or anoxia73. 233 
Broadly similar results were obtained in studies of perfused hearts from mice with a whole body 234 
knockout of AMPK-α274. Interestingly, left ventricular hypertrophy induced by phenylephrine was 235 
greatly accentuated in the hearts from AMPK-α2 knockout mice; this may have been due to less 236 
restraint on the mTORC1 pathway, because the basal phosphorylation of p70S6K at the mTORC1 237 
site was elevated, although it did not increase further upon phenylephrine treatment as in the 238 
controls75. 239 
Mutations in γ2 and γ3 subunits causing heart disease and altered glycogen content 240 
The only mutations in any of the seven genes encoding AMPK subunits clearly shown to cause 241 
human pathology are those in PRKAG2, encoding AMPK-γ2. These are associated with multiple 242 
cardiac disorders, specifically: (i) ventricular pre-excitation; (ii) excessive glycogen storage in 243 
cardiomyocytes; (iii) cardiac hypertrophy. Although rare, the PRKAG2 mutations are autosomal 244 
dominant in effect and therefore occur frequently in affected families. They are invariably missense 245 
mutations causing amino acid replacements, of which at least 14 have now been reported (Table 2). 246 
The affected residues are perfectly conserved between human γ1, γ2 and γ3, and occur in all four 247 
CBS repeats. The location of the residues affected in γ2, and of the three bound molecules of AMP, 248 
are mapped in Fig. 3 onto a structure for γ118. Interestingly, six of the mutations (R302Q, H383R, 249 
R384T, H530R, R531G and R531Q) affect basic residues whose side chains directly interact with 250 
the phosphate groups of one or more molecules of AMP or ATP, while two others also interact 251 
either directly (S548) or indirectly  (T400) with AMP18. Other affected residues lie in more 252 
peripheral regions of the γ subunit, and it is less obvious why their replacement should affect 253 
function. In the context of bacterially expressed CBS repeats from AMPK-γ2, the R302Q, H383R, 254 
T400N, and R531G mutations all reduced the affinity for ATP as well as AMP, with the severity of 255 
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the effects increasing in the order R302Q<H383R<T400N<R531G16. When expressed in 256 
mammalian cells as α1β1γ2 heterotrimers, these mutations also reduced allosteric activation by 257 
AMP, with the R531G mutation abolishing AMPK activation completely16, 76. The R384T and 258 
R531Q mutations were shown later to cause severe effects on AMPK function, similar to or even 259 
greater than R531G77, 78. In a comparison of the R531G and R531Q mutations expressed as α1β1γ2 260 
heterotrimers in HEK-293 cells, these mutations not only abolished allosteric activation by AMP, 261 
but also caused significant increases in basal Thr172 phosphorylation and activity78. This was 262 
particularly clear in cells stably expressing the R531G mutant, when clones could be selected in 263 
which the level of expression of the WT and mutant was identical; the R531G mutant consistently 264 
had a 2-fold higher basal Thr172 phosphorylation and activity although, unlike the wild type, it was 265 
completely insensitive to further activation by agents that increase cellular AMP/ADP33. 266 
 Some of the mutations, such as R302Q, can cause relatively mild symptoms so that the patients 267 
may not present in the clinic until early adulthood79. By contrast, patients with the R531G mutation 268 
develop quite severe symptoms during childhood80, while the R384T77 and R531Q78 mutations were 269 
only detected post mortem in neonates who had died within weeks of birth, and appeared to be de 270 
novo mutations because neither parent was affected. Consistent with the idea that R531G, R531Q 271 
and R384T cause particularly severe forms of the disease, these were the mutations with the largest 272 
effects on binding of AMP and ATP to the γ subunit16, 77, 78. It is also interesting that R531 and 273 
R384 are involved in the binding of AMP and/or ATP at the critical site, site 3. 274 
 What causes the cardiac sequelae of the PRKAG2 mutations? The reduction of AMP binding to 275 
the γ subunit causes reduced activation by AMP and is a loss-of-function effect, whereas the 276 
reduction of ATP binding may be responsible for the increased basal activity of the R531G and 277 
R531Q mutants and is a gain-of-function effect. Since these mutations are dominant, it seems likely 278 
that it is the gain-of-function effect, increased basal activity, that causes most of the pathology; the 279 
loss-of-function effect may be compensated for by γ1, which is the major isoform expressed in 280 
heart, at least in rodents81. This is an important conclusion because pharmaceutical companies are 281 
developing AMPK activators to combat Type 2 diabetes, and it suggests that activation of γ2-282 
containing complexes in the heart might have deleterious effects, as seen with these mutations. 283 
 Why does increased basal activity of γ2-containing complexes cause these cardiac phenotypes? 284 
AMPK is known to promote glucose uptake in cardiac muscle71, so increased basal activity would 285 
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be expected to cause a high basal uptake, even in the absence of a real demand for glucose. There is 286 
good evidence for this scenario from studies of transgenic mice over-expressing the N488I mutation 287 
in the heart, which develop ventricular pre-excitation and cardiac hypertrophy similar to the human 288 
disorder82. By 50 days of age, they have a 20-fold increase in cardiac glycogen compared with 289 
controls, accompanied by higher rates of glucose uptake and glycogen synthesis but lower rates of 290 
lactate production, suggesting that increased glucose uptake is being directed into glycogen 291 
synthesis rather than glycolysis. Glycogen synthase was also much more highly phosphorylated in 292 
the transgenic mice (presumably due to the high basal AMPK activity), but cellular glucose-6-293 
phosphate (G6P, an allosteric activator of glycogen synthase that over-rides the effects of 294 
phosphorylation) was also elevated >3-fold. Satisfying confirmation of this interpretation came 295 
when the N488I mice were crossed with knock-in mice carrying a mutation that renders glycogen 296 
synthase insensitive to G6P. The presence of the G6P-insensitive glycogen synthase reversed the 297 
high glycogen phenotype of the N488I mice and rescued the ventricular pre-excitation but not the 298 
cardiac hypertrophy, suggesting that the former but not the latter is secondary to increased glycogen 299 
content83. Supporting the idea that hyper-activation of the mTORC1 pathway was the cause of 300 
hypertrophy, mTORC1 targets such as p70S6K and 4EBP1 were more highly phosphorylated in the 301 
N488I mice, while treatment with rapamycin reduced, without completely preventing, the 302 
hypertrophy. Increased mTORC1 in the N488I mice is actually rather counter-intuitive, because 303 
AMPK is normally thought to inhibit that pathway67, 68. However, a recent study has suggested that 304 
AMPK can activate mTORC1 under certain circumstances by sustaining the supply of amino acids 305 
via autophagy84.  306 
 Why does abnormally high glycogen content lead to ventricular pre-excitation? During foetal 307 
development, the atria and the ventricles become separated by the growth of a fibrous layer called 308 
the annulus fibrosis, which ensures that the only electrical connection between the two chambers is 309 
via the atrioventricular node. In N488I mice the annulus fibrosis appeared to be thin and disrupted 310 
in places, and it was suggested that the presence of glycogen-containing vacuoles in myocytes 311 
disrupts its formation during fetal development, causing abnormal electrical connections between 312 
the atria and ventricles85. 313 
 Most mouse studies of γ2 mutations have involved transgenic mice over-expressing the 314 
mutations in human γ2. Although these mice do display the key clinical features of the human 315 
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syndrome, and mice expressing wild type γ2 from the same promoters were used as controls, they 316 
are not perfect models because γ2 is being over-expressed. Recently, three knock-in mouse models, 317 
in which mutations in the mouse gene equivalent to human R302Q, N488I or R531G are expressed 318 
globally, were studied86, 87. There was evidence for increased basal AMPK activity in liver and/or 319 
muscle of all three strains. The N488I and R531G mice displayed ventricular pre-excitation and 320 
modest increases in heart weight, which was associated with large increases in glycogen content in 321 
hearts of R531G but not the N488I mice. Both N488I and R531G mice displayed resistance to 322 
obesity and hepatic steatosis induced by high-fat diet, but, unlike the N488I mice, the R531G mice 323 
also displayed impaired renal function associated with glycogen accumulation, cyst formation, and 324 
inflammation and apoptosis in the kidney, particularly when on a high-fat diet87, By contrast, in the 325 
R302Q mice there was no obvious cardiac phenotype, but the homozygotes developed marked 326 
obesity as they aged, with smaller effects in heterozygotes. Obesity appeared to be due mainly to 327 
increased food intake through enhanced action of ghrelin, whose effects are mediated by AMPK 328 
activation via the CaMKK2 pathway in the hypothalamus88, 89. The homozygotes were also 329 
hypoinsulemic, apparently due to reduced glucose-stimulated insulin secretion from the pancreas. 330 
Overall, the phenotypes of these mice with knock-in mutations in the PRKAG2 gene showed 331 
surprising variability. Interestingly, heterozygous human carriers of the R302Q mutation, who have 332 
a relatively mild cardiac phenotype, also display some evidence of increased obesity, as well as 333 
higher fasting glucose and glycated haemoglobin (HbA1c) and lower insulin levels than unaffected 334 
siblings86. These non-cardiac features of the R302Q mutation only became evident following 335 
studies of the mouse model. 336 
 Finally, all of the residues mutated in AMPK-γ2 are also conserved in γ1 and γ3 (Table 2). It is 337 
interesting that none of them have yet been reported to be mutated in the human γ1 gene. However, 338 
mutations equivalent to R302Q have been found in both pigs and humans in the γ3 isoform, which 339 
is predominantly expressed in skeletal muscle81. In human muscle, γ3 appears to be present 340 
exclusively as the α2β2γ3 complex, which is the only form of AMPK that is activated during 341 
exercise6. An R200Q mutation (equivalent to R302Q in human γ2) was found to be a relatively 342 
common dominantly acting genetic variant in Hampshire pigs, and was associated with a high 343 
glycogen content in skeletal muscle; although adversely affecting meat quality, it did not cause 344 
obvious clinical problems90. Interestingly, in a screen of around 1500 humans, an R225W mutation 345 
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(R225 being the human equivalent of R302) was found in two apparently unrelated individuals, 346 
once again not associated with any obvious clinical defects; muscles from humans with this 347 
mutation had a higher basal AMPK activity, 2-fold higher glycogen content and lower triglyceride 348 
content91. In an in vitro study of myotubes from R225W carriers, they had 3-fold higher 349 
mitochondrial content and oxidative capacity, and 2-fold higher basal glucose uptake and glycogen 350 
synthesis rates than matched controls. The R225W subjects also had a remarkable resistance to 351 
fatigue during isometric contractions of the quadriceps92, suggesting that this mutation might confer 352 
an advantage during endurance exercise because of the high glycogen content. 353 
ROLE OF AMPK IN THE VASCULATURE 354 
In addition to the heart, it has become clear that AMPK has an important role in regulating vascular 355 
function, with distinct roles in the functions of vascular endothelial cells (ECs), smooth muscle cells 356 
(VSMCs), adventitial cells and vascular immune cells. 357 
Regulation of AMPK in endothelial and vascular smooth muscle cells 358 
AMPK-α1 accounts for the majority of total AMPK activity in ECs93-95, yet specific down-359 
regulation of AMPK-α2 still has marked effects96, 97.  A wide variety of physiological stimuli have 360 
been reported to activate endothelial AMPK, including hypoxia, low glucose and shear stress98-100, 361 
adiponectin101, angiotensin II and ghrelin102, 103. In addition, CaMKK2 mediates AMPK activation 362 
by vasoactive molecules including thrombin, VEGF, sphingosine-1-phosphate, bradykinin and 363 
estrogen104-108, suggesting that any stimulus that increases Ca2+ in ECs will activate AMPK. Finally, 364 
a number of widely used hypoglycemic (metformin, thiazolidinediones, salicylate, DPP4 inhibitors 365 
and liraglutide)109-112 and hypocholesterolemic (statins and fenofibrate)113, 114 drugs activate AMPK 366 
in cultured ECs. 367 
 Physiological signals that inhibit AMPK in ECs include high nutrient concentrations115-117, yet 368 
the mechanisms by which this inhibition of AMPK in ECs occurs are unclear, although increased 369 
PP2A-mediated dephosphorylation of AMPK has been proposed115. Endothelial AMPK may 370 
therefore be suppressed by the high levels of nutrients associated with obesity and insulin 371 
resistance. As protein kinase C (PKC) activation is associated with over-nutrition, it is interesting 372 
that PKC-mediated inhibitory phosphorylation of Ser487 on AMPK-α1 has been recently reported 373 
in ECs118. Conversely, the very first study of AMPK function in ECs demonstrated that AICAR 374 
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stimulated fatty acid oxidation119 and  AMPK activation was subsequently found to normalise 375 
impaired fatty acid oxidation and insulin signaling due to high glucose120. Stimulation of fat 376 
oxidation may partly underlie the effect of AMPK to antagonize palmitate-mediated endothelial 377 
dysfunction, thus protecting against lipotoxicity.  378 
 As with ECs, AMPK-α1 accounts for the majority of AMPK activity in murine and human 379 
VSMCs121, 122, and low glucose, adiponectin, estradiol and metformin all activate AMPK123-126. 380 
Angiotensin II has also been reported to acutely activate AMPK127, although prolonged activation 381 
had no effect128. Similar to ECs, high glucose inhibits AMPK in VSMCs, and IGF-1 also inhibits 382 
AMPK, most likely via inhibitory phosphorylation of AMPK-α1 by Akt129. Several studies have 383 
demonstrated that culture in phosphate/β-glycerophosphate, used to examine VSMC calcification as 384 
described later, also inhibits AMPK130, 131.  385 
AMPK and endothelial NO synthesis 386 
Endothelium-derived NO is a key regulator of vascular function, stimulating VSMC relaxation 387 
whilst inhibiting pro-inflammatory signaling, leukocyte adhesion, platelet aggregation, VSMC 388 
proliferation and migration associated with pathological vascular remodelling and 389 
atherosclerosis132. The first indication of a specific vascular role for AMPK came when AMPK was 390 
shown to phosphorylate at Ser1177 and activate endothelial NO synthase (eNOS), both in cell-free 391 
assays and in ECs93, 133. Multiple mechanisms regulate eNOS activity, including Ca2+/calmodulin 392 
binding, allosteric and protein:protein interactions, co-factor and substrate availability, 393 
phosphorylation, and subcellular localisation132. In addition to Ser1177, AMPK phosphorylates 394 
eNOS at Ser633, required for AICAR-stimulated NO synthesis in HEK293 cells134. NO synthesis 395 
requires dimerization of eNOS and sufficient tetrahydrobiopterin (BH4), in whose absence eNOS 396 
generates superoxide instead132. Another mechanism by which AMPK improves NO synthesis may 397 
be by enhancing BH4 levels, as AMPK prevents degradation of GTP cyclohydrolase I, which is the 398 
rate-limiting enzyme in BH4 synthesis135. AMPK can therefore act by multiple mechanisms to 399 
stimulate NO production (Fig. 4), although endothelial AMPK activation is not always associated 400 
with eNOS phosphorylation or NO synthesis94, 136. AMPK may also mediate some of the 401 
endothelial effects of NO, because NO donors activate AMPK in ECs96. 402 
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Endothelial AMPK and reactive oxygen species 403 
Inappropriate levels of reactive oxygen species (ROS), in particular superoxide anions generated in 404 
response to high concentrations of glucose, lipids and proinflammatory cytokines by NAD(P)H 405 
oxidase (Nox), uncoupled eNOS or mitochondrial respiratory chain complexes, have been 406 
implicated in vascular disease97, 135, 137, 138. Superoxide reacts with NO to form peroxynitrite, 407 
reducing NO bioavailability132. AMPK activation in ECs has been widely demonstrated to inhibit 408 
ROS formation, increase antioxidant defences and promote mitochondrial biogenesis. Down-409 
regulation of AMPK in ECs increased activity and expression of Nox97, whereas AMPK-dependent 410 
inhibition of Nox1/2 translocation to the plasma membrane has also been reported109. The 411 
mechanism by which AMPK inhibits Nox remains unclear, but may be secondary to reduced PKC-412 
mediated Nox activation, or NFκB-mediated Nox transcription97, 109. AMPK-dependent inhibition 413 
of mitochondrial ROS formation has also been reported in ECs maintained in high glucose 137, 414 
whereas AMPK-mediated stimulation of BH4 synthesis, as described above, prevents uncoupling of 415 
eNOS and superoxide formation135. Several groups have reported that AMPK-mediated inhibition 416 
of ROS in ECs is associated with increased levels of the antioxidant enzymes superoxide 417 
dismutase-2 (SOD2), catalase and thioredoxin 137, 139, 140. In ECs, AMPK activation reduces ER 418 
stress141, which is tightly linked to oxidative stress and inflammation, whereas silencing of AMPK 419 
increases markers of ER stress95.  Taken together, AMPK activation acts via multiple mechanisms 420 
to suppress chronic ROS synthesis in ECs, limiting their damaging actions as well as the 421 
sequestration of NO (Fig 4). 422 
AMPK and vascular cell inflammation  423 
The development of endothelial dysfunction and cardiovascular diseases is associated with elevated 424 
TNFα, IL-1β and IL-6142. TNFα and IL-1β stimulate activation of NFκB and the Jun N-terminal 425 
kinase (JNK) pathway, while IL-6 signals via Janus kinases (JAKs) leading to phosphorylation of 426 
signal transducer and activation of transcription (STAT) proteins143. The anti-inflammatory actions 427 
of AMPK in ECs were first described when AMPK activation was shown to suppress palmitate- or 428 
TNFα-stimulated NFκB activity117. Under basal conditions, NFκB is in an inactive form in the 429 
cytoplasm due to binding to IκB whereas, after cytokine stimulation, IκB phosphorylation by IκB 430 
kinase (IKK) targets it for degradation, allowing NFκB-mediated transcription of proinflammatory 431 
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cytokines, adhesion molecules and chemokines143, 144. NO inhibits endothelial NFκB activity145, 432 
suggesting that AMPK-stimulated NO synthesis would inhibit NFκB, although NO donors do not 433 
effectively suppress NFκB in ECs with reduced AMPK activity96. AMPK-α2 has been reported to 434 
phosphorylate IKKβ in vitro, inhibiting IκB phosphorylation and NFκB activation, with reduced IL-435 
1β-stimulated IKK phosphorylation observed in ECs lacking AMPK-α2 but not -α196. 436 
Alternatively, AMPK-mediated phosphorylation of the transcriptional co-activator p300 has been 437 
proposed to block acetylation and DNA binding by the p65 subunit of NFκB146. The idea that 438 
AMPK inhibits NFκB signalling is reinforced by functional studies demonstrating AMPK-439 
dependent inhibition of NFκB-regulated expression of adhesion molecules and MCP-196, 144.  Fewer 440 
studies have investigated the effect of AMPK on proinflammatory JNK and IL-6 signaling, 441 
although AICAR and metformin reduce JNK activity in ECs147, and increased JNK phosphorylation 442 
has been reported in ECs lacking AMPK-α295. The mechanism of JNK inhibition is uncertain, 443 
although AMPK-dependent inhibition of the upstream kinase MKK4 has been reported in other 444 
cells148. Recently, AMPK-dependent inhibition of IL-6-stimulated JAK-STAT signaling has been 445 
demonstrated in ECs, potentially via direct inhibitory phosphorylation of JAK1 by AMPK110. 446 
AMPK activation therefore appears to rapidly suppress multiple proinflammatory signaling 447 
pathways in ECs, by diverse mechanisms.  448 
 AMPK activation in VSMCs inhibits TNFα-stimulated NFκB activity and angiotensin II-449 
stimulated STAT1 activity, as well as reducing expression of inducible NOS and cyclooxygenase-2, 450 
and secretion of IL-6 and MCP-1149, 150. Thus, AMPK has anti-inflammatory effects in VSMCs as 451 
well as ECs. 452 
AMPK and angiogenesis 453 
Hypoxia, VEGF and adiponectin all stimulate AMPK-dependent EC migration, although there are 454 
conflicting reports as to whether this is mediated by NO94, 98, 101, 105, 108. Conversely, down-455 
regulation of AMPK attenuates angiogenesis caused by hypoxia, adiponectin, VEGF or statins, in 456 
either tube formation or matrigel plug assays94, 98, 101, 113. Mechanistically, increased UCP2 or SOD2 457 
have been reported to increase angiogenesis in AMPK-deficient ECs151, 152, indicating that down-458 
regulation of ROS may be critical. AMPK activation also stimulates VEGF expression, indicating 459 
that AMPK positively influences angiogenesis both by increasing VEGF levels and by increasing 460 
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VEGF signaling153. As angiogenesis would also consume significant amounts of ATP, AMPK 461 
activation might also serve a permissive role, ensuring adequate generation of ATP to permit EC 462 
migration and proliferation. 463 
AMPK and VSMC contraction 464 
AMPK has direct anti-contractile effects on VSMCs, because AICAR relaxes aortic rings in an NO- 465 
and endothelium-independent manner, an effect lost in AMPK-α1 knockouts121. Furthermore, 466 
AMPK activation has been reported to affect VSMC contractile signalling, including 467 
dephosphorylation of myosin light chain (MLC) and/or myosin phosphatase targeting subunit 1 468 
(MYPT1)125, 154. Mechanistically, MLC/MYPT1 dephosphorylation may be a consequence of 469 
AMPK-mediated inhibition and phosphorylation of RhoA at Ser188, causing subsequent inhibition 470 
of ROCK125. A769662 has also been reported to reduce intracellular Ca2+ in VSMCs by increasing 471 
sarco/endoplasmic Ca2+ ATPase (SERCA) activity, associated with increased phosphorylation of 472 
phospholamban on Thr17, which disinhibits SERCA and thereby may underlie SERCA activation 473 
and vessel relaxation155. 474 
AMPK and proliferation, differentiation and migration of VSMCs 475 
Unlike ECs, where AMPK up-regulates proliferation and migration thus supporting angiogenesis, in 476 
VSMCs AMPK inhibits proliferation in response to angiotensin II, PDGF and FCS, associated with 477 
stimulation of p53 Ser15 phosphorylation and reduced Rb phosphorylation128, 156. VSMCs from 478 
mice lacking AMPK-α2 exhibit increased proliferation, an effect mediated by increased degradation 479 
of the cyclin-dependent kinase inhibitor p27Kip1 triggered by the ubiquitin E3-ligase Skp2157. 480 
VSMCs retain significant plasticity in vivo and can exhibit a synthetic, proliferative phenotype 481 
rather than the quiescent, contractile phenotype observed during atherogenesis. AMPK not only 482 
suppresses VSMC proliferation, but also inhibits migration and maintains a pro-contractile 483 
phenotype158, 159. Inhibition of migration and proliferation are likely to be linked, because increased 484 
migration of VSMCs lacking AMPK-α2 is reported to be Skp2-dependent159.  Furthermore, AICAR 485 
limits neointima formation after wire injury of rat femoral arteries, which is likely to reflect the 486 
anti-proliferative, anti-migratory actions of AMPK on VSMCs127. 487 
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AMPK and VSMC calcification 488 
As mentioned above, culture in high phosphate/β-glycerophosphate concentrations is used 489 
experimentally to stimulate calcium deposition in VSMCs. In vivo, such vascular calcification is 490 
frequently associated with ageing, atherosclerosis and diabetes mellitus. AICAR, adiponectin and 491 
metformin all inhibit VSMC calcification in vitro130, 131, 160. In recent studies of atherosclerosis-492 
prone ApoE-/- mice, deletion of AMPK-α1 but not AMPK-α2 caused greater calcification of 493 
atherogenic plaques, and levels of the osteogenic transcription factor Runx2160. Furthermore, 494 
metformin reduced atherosclerotic calcification and Runx2 expression in the mice, an effect that 495 
was absent in ApoE-/- mice lacking AMPK-α1.  The authors of that study further demonstrated that 496 
VSMC-specific AMPK-α1 deletion in ApoE-/- mice phenocopied the increased calcification and 497 
Runx2 expression, whereas macrophage-specific AMPK-α1 deletion had no effect. The mechanism 498 
underlying the AMPK-mediated inhibition of Runx2 levels was further proposed to be mediated by 499 
phosphorylation of PIAS1 (protein inhibitor of activated STAT-1) at Ser510, which acts as a 500 
SUMO E3-ligase to trigger Runx2 SUMOylation and degradation160. 501 
ROLE OF AMPK IN THE VASCULATURE IN VIVO 502 
As many of the actions of AMPK in ECs and VSMCs should have beneficial effects on vascular 503 
function (Fig 5), considerable efforts have been made to examine whether AMPK influences 504 
vascular tone, remodelling and atherogenesis in vivo. Under physiological conditions, vascular 505 
AMPK has been reported to be activated in vivo by exercise161 and estradiol125, and is suppressed by 506 
high fat and fructose diets in rodents162, 163. Furthermore, exercise stimulates aortic AMPK 507 
phosphorylation in both ECs and VSMCs as assessed by immunohistochemistry161. 508 
AMPK and vascular tone 509 
As described above, AMPK can stimulate NO synthesis by ECs and independently inhibit 510 
contractile protein function in VSMCs in vitro. In intact arterial vessels, AICAR stimulates 511 
vasodilation in a diverse range of vascular beds from several species121, 164-167, an effect greatly 512 
attenuated in mice lacking AMPK-α1121. The mechanism of AICAR-stimulated vasodilation 513 
remains uncertain, and has been variously reported to be endothelium- and NO-dependent164, 167, 514 
partially NO- and endothelium-dependent165, 166 or NO- and endothelium-independent121. Using 515 
endothelium-specific knockouts it has been proposed that AMPK-α1 is important for endothelium-516 
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dependent hyperpolarisation-mediated relaxation of resistance arteries168. Interestingly, resistance 517 
arteries exhibited endothelium-independent dilation in response to A769662155, suggesting a 518 
VSMC-mediated effect. It is possible that ECs and VSMCs exhibit differential sensitivities to 519 
AICAR and A769662, or that some of these may be AMPK-independent effects. Despite studies 520 
indicating that AMPK-α2 has a less important role in regulation of vascular tone121, 168, AMPK-α2 521 
knockout mice are hypertensive and exhibit increased contractile responses to phenylephrine in 522 
aortic rings169. Furthermore, impaired bradykinin-dependent vasodilation has been described in EC-523 
specific AMPK-α2 knockout mice, thought to be due to increased bradykinin degradation by 524 
angiotensin-converting enzyme activity170. AICAR rapidly reduced blood pressure in spontaneously 525 
hypertensive rats, but was without effect in normotensive controls165, while prolonged 526 
administration of AICAR reduced systolic blood pressure in obese Zucker rats171. These data 527 
support a role for AMPK in the regulation of vascular tone in disease models, but cannot exclude 528 
systemic actions on the heart, kidney or other tissues. Surprisingly, whether systemic administration 529 
of more selective AMPK activators, such as A769662, 991 or C13, alters vascular tone has yet to be 530 
reported. More recently it has become clear that perivascular adipose tissue (PVAT), which is 531 
removed in most myography protocols, has a paracrine anti-contractile effect on the underlying 532 
vessel. AMPK activity in resistance arteries has been shown to alter the influence of PVAT-derived 533 
mediators172 and the anti-contractile action of PVAT is absent in mice lacking AMPK-α1, perhaps 534 
due to reduced adiponectin secretion173.  AMPK in ECs, VSMCs and adventitial PVAT may 535 
therefore all contribute to the maintenance of vascular tone, but the cell type that mediates actions 536 
of AMPK on vascular tone may change, depending on the location of the vessel. 537 
AMPK and atherosclerosis 538 
The potential anti-atherogenic actions of AMPK have been investigated in vascular injury models 539 
and atherosclerosis-prone hypercholesterolemic mice. AICAR attenuates post-ischaemic leukocyte 540 
rolling and adhesion to the endothelium in vivo, an effect lost in AMPK-α1 or AMPK-α2 knockout 541 
mice174, and systemic administration of AICAR or metformin reduces atherosclerotic lesion size, 542 
macrophage accumulation and inflammation175-177. Similarly, berberine reduced the severity of 543 
atherosclerotic lesions in atherosclerosis-prone mice, an effect attenuated in AMPK-α2 544 
knockouts178. AMPKα2-deficient mice also exhibited increased atherosclerosis95, although the 545 
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global deficiency makes it difficult to assess whether this was due to a direct effect on vascular 546 
tissues. With respect to plaque stability and progression, recent studies have yielded exciting 547 
results. Metformin reduced plaque calcification, and mice with a SMC-specific knockout of 548 
AMPK-α1 had exacerbated calcification of atherosclerotic plaques in brachiocephalic arteries, 549 
phenocopying the increased calcification observed in global AMPK-α1 but not AMPK-α2 550 
knockouts160. As the clinical use of metformin is associated with reduced macrovascular morbidity 551 
and mortality independently of glycemia179, these results may help to define the pathways involved. 552 
Using a ligation model for studying injury-induced neointima stability in brachiocephalic arteries, 553 
mice with deletion of AMPK-α1 but not AMPK-α2 exhibited more occlusive lesions, with lower 554 
collagen and higher macrophage content, indicative of plaque instability180. Similarly, in a high fat 555 
diet model, SMC-specific AMPK-α2 knockouts exhibited features of unstable plaques, including 556 
phenotype switching of VSMCs158. These data therefore indicate that AMPK activation may not 557 
only inhibit atherogenesis, but also inhibit the generation of vulnerable, calcified plaques. Repair of 558 
damaged endothelium is also considered important to prevent endothelial dysfunction after injury, 559 
and EC-specific expression of constitutively active AMPK has also been reported to promote re-560 
endothelialization in a wire injury model, attributable in part to increased mobilization and 561 
incorporation of endothelial progenitor cells181.  562 
 Immune cells are involved in all stages of atherosclerosis, and AMPK suppresses inflammatory 563 
signalling, monocyte-to-macrophage differentiation and foam cell formation175, 177, 182. Indeed, 564 
myeloid-specific AMPK-α1 knockout mice fed an atherogenic diet on a LDL receptor knockout 565 
background have recently been shown to exhibit exacerbated atherosclerosis, with increased plaque 566 
macrophage content and inflammatory gene expression182. All of these studies suggest that AMPK 567 
activation limits atherosclerosis, although all of the results are from rodent models, rather than 568 
humans. One intriguing question is how, despite only contributing a small fraction of total AMPK 569 
activity in vascular cells, specific down-regulation of AMPK-α2 has such marked effects on 570 
atheroma development in mice 95, 158, 174, 178, similar to the specific effects noted with respect to 571 
vascular tone169, 170. It remains to be determined whether there are isoform-specific substrates or 572 
specific subcellular localisations that contribute to the vascular function of AMPK-α2. 573 
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AMPK and pulmonary vascular remodelling 574 
Several studies have identified a critical role for AMPK in the pulmonary vascular remodelling and 575 
perivascular inflammation that characterizes pulmonary arterial hypertension (PAH). Metformin 576 
reduces pulmonary artery VSMC proliferation in an AMPK-dependent manner183, and inhibits the 577 
vascular remodelling of pulmonary arteries in rodent models of PAH184, 185 . Mice with an EC-578 
specific lack of AMPK also exhibit accelerated pulmonary remodeling185. Whether the beneficial 579 
action of metformin in PAH is mediated by AMPK remains to be determined. By contrast, AMPK 580 
activation by hypoxia may contribute to the development of PAH by promoting pulmonary VSMC 581 
survival186, while AMPK-mediated inhibition of the voltage-gated K+ channel Kv1.5 may underlie 582 
the acute detrimental effects of hypoxia on PAH187. 583 
Conclusions and Perspectives 584 
AMPK exists as heterotrimeric complexes consisting of catalytic α subunits and regulatory β and γ 585 
subunits. AMPK complexes sense the energy status of cells by sensing increases in the cellular 586 
AMP:ATP and/or ADP:ATP ratios. AMP, ADP and ATP bind at up to three sites on the γ subunits; 587 
binding of AMP and/or ADP causes activation by promoting net phosphorylation at Thr172 within 588 
the activation loop on the α subunit, while binding of AMP only causes further allosteric activation. 589 
Once activated by energy stress, AMPK switches on catabolic pathways that generate ATP, while 590 
switching off cell growth and proliferation and other processes that consume ATP. 591 
 AMPK appears to exert a protective effect in rodent heart during ischemic episodes. Inherited 592 
and/or de novo mutations in the PRKAG2 gene (encoding AMPK-γ2) in humans cause heart disease 593 
of varying severity characterized by ventricular pre-excitation, excessive cardiac glycogen content, 594 
and hypertrophy. The mutations cause an increase in basal AMPK activity, leading to increased 595 
glucose uptake that accounts for the first two abnormalities. They also cause a failure of γ2-596 
containing complexes to be further activated by AMP, which might explain the hypertrophy 597 
through unrestrained activity of the mTORC1 pathway. 598 
 In blood vessels, AMPK inactivation is associated with anti-contractile, anti-inflammatory and 599 
anti-atherogenic actions on both the vascular endothelium and smooth muscle. Exciting recent 600 
studies link AMPK activation to increased stability and reduced calcification of atherosclerotic 601 
plaques as well as highlighting a potential role for AMPK in pulmonary arterial hypertension. 602 
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Given the critical role of AMPK in the regulation of nutrient metabolism, therapies that activate 603 
AMPK may not only normalise metabolic dysfunction but also reduce the burden of cardiovascular 604 
complications in obesity and type 2 diabetes. Recent studies using vascular tissue-specific deletion 605 
of AMPK-α isoforms are beginning to elucidate specific roles for AMPK-α isoforms, yet despite 606 
the wealth of research demonstrating the functional cardiovascular consequences of AMPK 607 
activation, the AMPK substrates involved and underlying mechanisms in several cases remain 608 
poorly defined. Emerging technologies such as phosphoproteomics may prove beneficial in 609 
understanding such mechanisms after AMPK up- or down-regulation in cardiovascular tissues in 610 
different disease settings and disease models. 611 
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FIGURE LEGENDS 1279 
Figure 1: Domain layouts of AMPK subunits and their isoforms. The linear layout of domains 1280 
is shown, approximately to scale and with similar color coding as in Fig. 2. Note that 1281 
both β subunits are N-myristoylated, and that the γ2 and γ3 subunit isoforms have 1282 
unrelated N-terminal extensions of unknown function, although both are also reported 1283 
to exist as shorter, N-terminally truncated versions due to alternate start sites and/or 1284 
splicing188. 1285 
Figure 2: Structure of human AMPK (α1β2γ1 complex)7. The model was created in 1286 
spacefilling mode using PyMol v1.7.4.2 with the co-ordinates in PDB file 4RER, and 1287 
with color coding similar to Fig. 1. The heterotrimer was crystallized in the presence of 1288 
β-cyclodextrin, which occupies the glycogen-binding site, staurosporine, which 1289 
occupies the active site, and AMP, which occupies sites 1, 3 and 4 on the γ subunit 1290 
(sites 1 and 4 are round the back in this view). Although Thr172 was phosphorylated, it 1291 
is not visible in this view but lies in the cleft between the α subunit C lobe and the β-1292 
CTD, just over the right-hand “shoulder” of the C-lobe. 1293 
Figure 3: Two views of the structure of the four CBS repeats of the γ1 subunit. The model 1294 
used the co-ordinates in PDB file 2V8Q18, and was rendered in PyMol v1.7.4.2 with the 1295 
γ1 subunit in cartoon view. The two views are rotated 180o around the x axis (dashed 1296 
line) with respect to each other, with the orientation of the top view being similar to that 1297 
in Fig. 2. Note the pseudosymmetrical layout of the four CBS repeats, which are colored 1298 
differently (and differently to Figs. 1 and 2). Residues equivalent to those mutated in γ2 1299 
are highlighted using the “dots” version of space-filling representation, and are 1300 
numbered using the human γ2 numbering. The three molecules of bound AMP are 1301 
labelled and are shown in standard space-filling view, with C atoms green, O red and N 1302 
blue. 1303 
Figure 4:  Regulation of endothelial NO and superoxide synthesis by AMPK. AMPK 1304 
activation stimulates NO synthesis via multiple mechanisms: (i) phosphorylation of 1305 
eNOS at Ser633 and Ser1177; (ii) increasing Hsp90 association with eNOS; (iii) 1306 
increasing BH4 concentrations via GTP cyclohydrolase I (GTPCH1); (iv) reducing 1307 
superoxide synthesis via inhibition of Nox and increasing antioxidant protein 1308 
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(superoxide dismutase (SOD), thioredoxin and catalase) levels. NO itself is also 1309 
reported to activate AMPK. 1310 
 1311 
Figure 5:  Actions of AMPK in vascular cells. Physiological activators of AMPK in ECs include 1312 
hypoxia/ischemia, shear stress, adiponectin, thrombin, bradykinin and VEGF (synthesis 1313 
of which is stimulated by AMPK in other tissues). AMPK is reported to stimulate 1314 
VSMC relaxation through: (i) increased NO synthesis and possibly endothelium-1315 
dependent hypopolarising factor (EDHF); (ii) inhibition of MYPT1/MLC 1316 
phosphorylation and Ca2+ levels in VSMCs, reported to be mediated by reduced RhoA 1317 
activity and increased sarco/endoplasmic Ca2+ ATPase (SERCA) activity respectively. 1318 
AMPK activation in ECs stimulates proliferation and migration, whereas in VSMCs, 1319 
proliferation and migration are inhibited, associated with p53 phosphorylation, Rb 1320 
dephosphorylation and p27(Kip1) stabilisation. AMPK also inhibits VSMC 1321 
calcification by reducing Runx2 and pro-inflammatory signalling pathways leading to 1322 
leukocyte adhesion and cytokine/chemokine synthesis. 1323 
  1324 
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Table 1: List of pharmacological agents commonly used to activate AMPK in intact cells or 1325 
in vivo, and their mechanisms of action. 1326 
 1327 
Class Agent Mechanism Binding site used Isoform-selective? Ref. 
1 metformin mitochondrial inhibitor, AMP ↑ γ subunit (binds AMP) 
No 33 
1 phenformin mitochondrial inhibitor, AMP ↑ γ subunit (binds AMP) 
No 33 
1 berberine mitochondrial inhibitor, AMP ↑ γ subunit (binds AMP) 
No 33 
2 2-deoxyglucose glycolytic inhibitor, AMP ↑ γ subunit (binds AMP) 
No 33 
3 AICAR pro-drug, converted to ZMP γ subunit (binds ZMP) 
No 33, 34 
4 C13 pro-drug, converted to C2 γ subunit (binds C2) 
α1-selective 38, 40 
5 A769662 direct activator ADaM site 
β1-selective 189 
5 991 direct activator ADaM site 
β1>β2 8 
5 MT 63-78 direct activator ADaM site 
β1-selective 190 
5 PF-06409577 direct activator ADaM site β1-selective 191 
5 PF-249 direct activator ADaM site β1-selective 191 
5 salicylate direct activator ADaM site β1-selective 9, 44 
   1328 
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Table 2: Amino acid replacements, generated by mutations in PRKAG2, that are associated 1329 
with heart disorders. Equivalent residues in the sequences of human γ1 and γ3 are 1330 
shown in the second and third column and the CBS repeat affected in the fourth. V336 1331 
and R350 are located in the linker between CBS1 and CBS2. 1332 
 1333 
γ2 mutation γ1 equivalent  γ3 equivalent CBS repeat affected Reference 
R302Q R70 R225 CBS1 192-194 
S333P S101 S333 CBS1 79 
V336A V104 V259 linker 79 
L insert (after R350) after R118 after R273 linker 195 
H383R H151 H306 CBS2 195 
R384T R152 R307 CBS2 77 
T400N T168 T323 CBS2 193 
Y487H Y255 Y410 CBS3 196 
N488I N256 N411 CBS3 193 
E506K E274 E429 CBS4 79, 197 
H530R H298 H453 CBS4 198 
R531G R299 R454 CBS4 80 
R531Q R299 R454 CBS4 78 
S548P S316 S471 CBS4 199 
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